Constellation pharma had a Bromodomain and Extra-Terminal (BET) protein inhibitor called Pelabresib for MF and MDS.Morphosys acquired Constellation for $1.7Bn in June 2021.Next Novartis acquired Morphosys in Feb 2024 for US $2.92 Bn (EUR $2.7 Bn)The focus of these acquisitions is the combined MF and MDS trial being trialled in combination with JAK inhibitor (Ruxolitinib)- https://clinicaltrials.gov/study/NCT02158858No.of patients: 336In the 1/7/24 preso slide 11, Gary has this transaction as successful phase 3- details of the trials here- https://clinicaltrials.gov/study/NCT04603495Syntara SNT-5505 in MF: https://clinicaltrials.gov/study/NCT04676529We are also doing a combination trial with the JAK inhibitor ruxolitinibNo.of patients: 39
From the looks of it, Constellation’s and Syntara’s MF trials have similar endpoints (at a high level) although vastly different patient populations.So yes, at the December readout we may be in the crosshairs of some BPs.AIMO. DYOR.
- Forums
- ASX - By Stock
- SNT
- SNT - Research & Valuation
SNT
syntara limited
Add to My Watchlist
48.3%
!
3.0¢

SNT - Research & Valuation
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
3.0¢ |
Change
-0.028(48.3%) |
Mkt cap ! $48.01M |
Open | High | Low | Value | Volume |
5.4¢ | 5.4¢ | 2.9¢ | $2.206M | 70.64M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
14 | 1677985 | 2.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
3.0¢ | 1345995 | 12 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
13 | 1652985 | 0.029 |
32 | 5060034 | 0.028 |
17 | 3312545 | 0.027 |
14 | 939113 | 0.026 |
11 | 2192000 | 0.025 |
Price($) | Vol. | No. |
---|---|---|
0.030 | 1345912 | 11 |
0.031 | 1371761 | 10 |
0.032 | 963790 | 6 |
0.033 | 1022727 | 6 |
0.034 | 470000 | 2 |
Last trade - 15.01pm 11/08/2025 (20 minute delay) ? |
Featured News
SNT (ASX) Chart |
The Watchlist
WIN
WIN METALS LTD
Steve Norregard, CEO & MD
Steve Norregard
CEO & MD
SPONSORED BY The Market Online